IceCure Medical (NASDAQ:ICCM – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $3.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 140.00% from the stock’s previous close.
IceCure Medical Trading Down 1.6 %
NASDAQ ICCM opened at $1.25 on Tuesday. The company has a fifty day simple moving average of $1.30 and a two-hundred day simple moving average of $1.04. The stock has a market cap of $57.03 million, a P/E ratio of -3.38 and a beta of 0.75. IceCure Medical has a 12-month low of $0.52 and a 12-month high of $1.57. The company has a current ratio of 4.03, a quick ratio of 3.41 and a debt-to-equity ratio of 0.03.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in ICCM. UBS Group AG raised its holdings in shares of IceCure Medical by 1,302.3% during the fourth quarter. UBS Group AG now owns 28,986 shares of the company’s stock worth $45,000 after purchasing an additional 26,919 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of IceCure Medical by 57.2% during the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock worth $86,000 after purchasing an additional 20,159 shares during the last quarter. Boothbay Fund Management LLC raised its holdings in shares of IceCure Medical by 100.0% during the fourth quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock worth $62,000 after purchasing an additional 20,000 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of IceCure Medical during the second quarter worth $78,000. Hedge funds and other institutional investors own 0.34% of the company’s stock.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Read More
- Five stocks we like better than IceCure Medical
- Manufacturing Stocks Investing
- Is UnitedHealth Group Stock a Strong Buy or a Falling Knife?
- Golden Cross Stocks: Pattern, Examples and Charts
- Lemonade Stock: Unusual Call Volume Highlights Sweet Trade
- Investing in Commodities: What Are They? How to Invest in Them
- Cathie Wood Likes UiPath Stock Over NVDA, Should You?
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.